Details for Patent: 11,020,382
✉ Email this page to a colleague
Which drugs does patent 11,020,382 protect, and when does it expire?
Patent 11,020,382 protects OXBRYTA and is included in two NDAs.
This patent has ten patent family members in eight countries.
Summary for Patent: 11,020,382
| Title: | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde |
| Abstract: | Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzal- dehyde (Compound 1), or a polymorph thereof, in certain dosing regimens. |
| Inventor(s): | Ramos; Eleanor L. (South San Francisco, CA), Lehrer-Graiwer; Joshua Eli (South San Francisco, CA), Hutchaleelaha; Athiwat (South San Francisco, CA) |
| Assignee: | Global Blood Therapeutics, Inc. (South San Francisco, CA) |
| Application Number: | 15/368,142 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
More… ↓ |
Drugs Protected by US Patent 11,020,382
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Subscribe | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Subscribe | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Subscribe | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Subscribe | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,020,382
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112018011272 | ⤷ Subscribe | |||
| European Patent Office | 3383392 | ⤷ Subscribe | |||
| Israel | 259798 | ⤷ Subscribe | |||
| Morocco | 43373 | ⤷ Subscribe | |||
| Mexico | 2018006832 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
